MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin

Biochem Pharmacol. 2021 Nov:193:114744. doi: 10.1016/j.bcp.2021.114744. Epub 2021 Aug 25.

Abstract

Purpose: Cardiac transition from concentric (C-LVH) to eccentric left ventricle hypertrophy (E-LVH) is a maladaptive response of hypertension. Matrix metalloproteinases (MMPs), in particular MMP-2, may contribute to tissue remodeling by proteolyzing extra- and intracellular proteins. Troponin I and dystrophin are two potential targets of MMP-2 examined in this study and their proteolysis would impair cardiac contractile function. We hypothesized that MMP-2 contributes to the decrease in troponin I and dystrophin in the hypertensive heart and thereby controls the transition from C-LVH to E-LVH and cardiac dysfunction.

Methods: Male Wistar rats were divided into sham or two kidney-1 clip (2K-1C) hypertensive groups and treated with water (vehicle) or doxycycline (MMP inhibitor, 15 mg/kg/day) by gavage from the tenth to the sixteenth week post-surgery. Tail-cuff plethysmography, echocardiography, gelatin zymography, confocal microscopy, western blot, mass spectrometry, in silico protein analysis and immunofluorescence were performed.

Results: 6 out of 23 2K-1C rats (26%) had E-LVH followed by reduced ejection fraction. The remaining had C-LVH with preserved cardiac function. Doxycycline prevented the transition from C-LVH to E-LVH. MMP activity is increased in C-LVH and E-LVH hearts which was inhibited by doxycycline. This effect was associated with an increase in troponin I cleavage products and a decline in dystrophin in the left ventricle of E-LVH rats, which was prevented by doxycycline.

Conclusion: Hypertension causes increased cardiac MMP-2 activity which proteolyzes troponin I and dystrophin, contributing to the transition from C-LVH to E-LVH and cardiac dysfunction.

Keywords: Cardiac hypertrophy; Dystrophin; Hypertension; Matrix metalloproteinase; Troponin I.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Doxycycline / pharmacology*
  • Dystrophin / genetics
  • Dystrophin / metabolism*
  • Gene Expression Regulation, Enzymologic / drug effects
  • Hypertension / complications*
  • Hypertrophy, Left Ventricular / etiology*
  • Hypertrophy, Left Ventricular / metabolism
  • Male
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 2 / metabolism*
  • Matrix Metalloproteinase Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Troponin I / genetics
  • Troponin I / metabolism*

Substances

  • Anti-Bacterial Agents
  • Dystrophin
  • Matrix Metalloproteinase Inhibitors
  • Troponin I
  • Matrix Metalloproteinase 2
  • Mmp2 protein, rat
  • Doxycycline